ATE404556T1 - SUBSTITUTED HYDANTOINS - Google Patents

SUBSTITUTED HYDANTOINS

Info

Publication number
ATE404556T1
ATE404556T1 AT05771890T AT05771890T ATE404556T1 AT E404556 T1 ATE404556 T1 AT E404556T1 AT 05771890 T AT05771890 T AT 05771890T AT 05771890 T AT05771890 T AT 05771890T AT E404556 T1 ATE404556 T1 AT E404556T1
Authority
AT
Austria
Prior art keywords
substituted hydantoins
hydantoins
substituted
Prior art date
Application number
AT05771890T
Other languages
German (de)
Inventor
Xin-Jie Chu
Nader Fotouhi
Nicholas Huby
Norman Kong
Lee Mcdermott
John Moliterni
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE404556T1 publication Critical patent/ATE404556T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
AT05771890T 2004-08-17 2005-08-09 SUBSTITUTED HYDANTOINS ATE404556T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60217504P 2004-08-17 2004-08-17
US68299705P 2005-05-20 2005-05-20

Publications (1)

Publication Number Publication Date
ATE404556T1 true ATE404556T1 (en) 2008-08-15

Family

ID=35589619

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05771890T ATE404556T1 (en) 2004-08-17 2005-08-09 SUBSTITUTED HYDANTOINS

Country Status (16)

Country Link
US (1) US7427635B2 (en)
EP (1) EP1781649B1 (en)
JP (1) JP4927733B2 (en)
KR (2) KR20090006885A (en)
AR (1) AR050297A1 (en)
AT (1) ATE404556T1 (en)
AU (1) AU2005274390B2 (en)
BR (1) BRPI0514515A (en)
CA (1) CA2576599A1 (en)
DE (1) DE602005008986D1 (en)
ES (1) ES2313389T3 (en)
MX (1) MX2007001846A (en)
PL (1) PL1781649T3 (en)
RU (1) RU2383542C2 (en)
TW (1) TW200621764A (en)
WO (1) WO2006018188A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
CA2686756A1 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
WO2009021887A1 (en) 2007-08-16 2009-02-19 F. Hoffmann-La Roche Ag Substituted hydantoins
MX2010006331A (en) * 2007-12-20 2010-07-05 Hoffmann La Roche Substituted hydantoins as mek kinase inhibitors.
HUE043569T2 (en) * 2008-06-16 2019-08-28 Univ Tennessee Res Found Compounds for the treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
WO2011000945A2 (en) * 2009-07-03 2011-01-06 Nensius Research A/S Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns
KR20120130777A (en) 2010-03-01 2012-12-03 유니버시티 오브 테네시 리서치 파운데이션 Compounds for treatment of cancer
EA030276B1 (en) 2010-03-09 2018-07-31 Дана-Фарбер Кэнсер Инститьют, Инк. Methods of identifying patients suffering from cancer and treating cancer in patients having or developing resistance to a first cancer therapy
JP5960683B2 (en) 2010-04-28 2016-08-02 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ketoheteroarylpiperidine and -piperazine derivatives as fungicides
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
WO2020060112A1 (en) * 2018-09-17 2020-03-26 Yungjin Pharm. Co., Ltd. Novel thiazole derivatives and pharmaceutically acceptable salts thereof
US20230095520A1 (en) * 2020-03-13 2023-03-30 Yungjin Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating cancer comprising azole derivatives or pharmaceutically acceptable salt thereof
KR102335637B1 (en) * 2020-03-13 2021-12-06 영진약품 주식회사 Novel compounds of inhibiting cdk7, and their pharmaceutically acceptable salts
KR20210146144A (en) 2020-05-26 2021-12-03 엘지전자 주식회사 Cart part

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
AU757046B2 (en) 1997-07-01 2003-01-30 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
JP3842131B2 (en) * 2000-05-03 2006-11-08 エフ．ホフマン−ラ ロシュ アーゲー Hydantoin-containing glucokinase activator
BR0211265A (en) * 2001-07-19 2004-07-20 Pharmacia Italia Spa Phenylacetamido thiazole derivatives, process for their preparation and use as antitumor agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors

Also Published As

Publication number Publication date
US20060041146A1 (en) 2006-02-23
AR050297A1 (en) 2006-10-11
KR20070034635A (en) 2007-03-28
ES2313389T3 (en) 2009-03-01
KR100889721B1 (en) 2009-03-23
DE602005008986D1 (en) 2008-09-25
WO2006018188A2 (en) 2006-02-23
JP4927733B2 (en) 2012-05-09
EP1781649A2 (en) 2007-05-09
CA2576599A1 (en) 2006-02-23
AU2005274390A1 (en) 2006-02-23
US7427635B2 (en) 2008-09-23
JP2008509950A (en) 2008-04-03
AU2005274390B2 (en) 2012-01-19
BRPI0514515A (en) 2008-06-10
EP1781649B1 (en) 2008-08-13
MX2007001846A (en) 2007-03-28
PL1781649T3 (en) 2009-01-30
TW200621764A (en) 2006-07-01
KR20090006885A (en) 2009-01-15
WO2006018188A3 (en) 2006-05-18
RU2007109651A (en) 2008-09-27
RU2383542C2 (en) 2010-03-10

Similar Documents

Publication Publication Date Title
ATE404556T1 (en) SUBSTITUTED HYDANTOINS
ATE414693T1 (en) NOVEL CIS-IMIDAZOLINES
DE602005012636D1 (en) TION
ATE440097T1 (en) SUBSTITUTED HYDANTOINS FOR CANCER TREATMENT
DK1828514T3 (en) Hinge
DK1630309T3 (en) Drain
DE502005005196D1 (en) DIRECTLY FIXED COMPONENTS
ATE404546T1 (en) SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXYACETAMIDE COMPOUNDS
DE502006005182D1 (en) Heterocyclicamide-substituted imidazole
NO20070299L (en) Novel heterocyclic compounds
DE502005004534D1 (en) comber
DE602005004472D1 (en) compensation arrangement
DE112005002826A5 (en) compensation unit
AT500198B1 (en) LADEWAGEN
DK1577449T3 (en) drain connection
ATE389633T1 (en) OMEGA-PHENYLOCTANAMIDE
AT500249A3 (en) SCHEIBENEGGE
ATA2632004A (en) Straw
SE0400785L (en) Compensating device
DE502005002684D1 (en) DIOXAZINYL-SUBSTITUTED THIENYL SULPHONYLAMINOCARBONYL COMPOUNDS
ATA10692004A (en) HINGE
DE102005063244A8 (en) Modified 2-nitroimidazole derivative
NO20044198D0 (en) microphone
FI20060839A (en) Twin-wire
FR2867906B1 (en) DISTRIBUTOR

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1781649

Country of ref document: EP